Trials Sponsors Conditions Drugs Pricing

Conditions

Obesity or Overweight Diabetes Mellitus, Type 2 Obesity or overweight Diabetes Mellitus, Type 2

Keywords

ObesityOverweightAZD6234LenbelintideDiabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (1)

Percent change in body weight from baseline at 68 weeks of treatment.
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
68 weeks

Secondary Outcomes (8)

Absolute change in weight (kg) from baseline at 68 weeks of treatment
68 weeks
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
68 weeks

Study Arms (3)

AZD6234 Dose 1

EXPERIMENTAL

AZD6234 Dose 1

Drug: Lenbelintide

AZD6234 Dose 2

EXPERIMENTAL

AZD6234 Dose 2

Drug: Lenbelintide

Placebo

PLACEBO COMPARATOR

Matching placebo

Drug: Placebo

Interventions

LenbelintideDrug

IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

Also known as: AZD6234

AZD6234 Dose 1AZD6234 Dose 2

PlaceboDrug

Placebo matching IMP dose injected subcutaneously, once a week.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Males \& females (inclusive of all gender identities) age ≥18 years
BMI ≥27 kg/m2

Sponsors & Collaborators

AstraZeneca
Industrylead
AstraZeneca AB
Industrylead

Study Sites (230)

Research Site

Fairhope, Alabama, 36532, United States

RECRUITING

Research Site

Huntsville, Alabama, 35801, United States

NOT_YET_RECRUITING

Research Site

Mobile, Alabama, 36608, United States

NOT_YET_RECRUITING

Research Site

Mesa, Arizona, 85213, United States

MeSH Terms

Conditions

ObesityOverweightDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Central Study Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 6, 2026

First Posted

August 25, 2026

Study Start

August 20, 2026

Actual (reported)

Primary Completion

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (3)

AZD6234 Dose 1

AZD6234 Dose 2

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (230)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source records

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (3)

AZD6234 Dose 1

AZD6234 Dose 2

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (230)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source records

Locations